For patients with dwarfism who opt to go through limb lengthening treatment, it’s very important they go to an institute where there is a team of experts specialized in not only limb lengthening, but dwarfism as well. In his presentation, Dr. Herzenberg will give an in-depth overview of how limb alignment and limb lengthening are […]

John E. Herzenberg, MD, FRCSC, FAAOS Director of Pediatric Orthopedics
International Center for Limb Lengthening; Rubin Institute for Advanced Orthopedics; Sinai Hospital

Limb lengthening has been available to patients with dwarfism for several decades now. Just like how pharmaceutical treatments are being developed for achondroplasia, limb lengthening treatment is constantly advancing as well – having a less invasive approach due to new techniques that are being developed daily. In his presentation, Dr. Standard will highlight what patients […]

Shawn C. Standard, MD, FAAOS Head of Pediatric Orthopedics
International Center for Limb Lengthening; Rubin Institute for Advanced Orthopedics; Sinai Hospital

Limb lengthening is sometimes seen as a controversial procedure for those with dwarfism, mostly due to misinformation about the procedure itself. Dr. McClure is here to answer your most pressing questions about all things limb lengthening for dwarfism, as well as debunk any myths there are.

Philip K. McClure, MD, FAAOS Assistant Director
International Center for Limb Lengthening; Rubin Institute for Advanced Orthopedics; Sinai Hospital

Physical therapy is a critical part of deformity correction (bowed legs) and limb lengthening treatment and recovery. At the International Center for Limb Lengthening, Anil Bhave leads a team of physical and occupational therapists specializing in treating patients with achondroplasia going through these procedures.  Rehabilitation and Physical Therapy at the International Center for Limb Lengthening

Anil Bhave, PT Clinical Director of Orthopedic Rehabilitation; Director of Wasserman Gait Laboratory
International Center for Limb Lengthening; Rubin Institute for Advanced Orthopedics; Sinai Hospital

The latest information on Vosoritide for Achondroplasia. Vosoritide is an investigational analog of C-type Natriuretic Peptide (CNP) under evaluation for the treatment of children with achondroplasia, the most common form of skeletal dysplasia.   

Laura Guido, PharmD Medical Director, Global Medical Affairs
BioMarin Pharmaceutical Inc.

The latest information on Pfizer‘s pipeline for Recifercept, “a biologic medicine that targets mutated fibroblast growth factor Receptor 3 (FGFR3).” 

Christian Czech, PhD Senior Director, Head of Research
Pfizer

The latest information on the development of TransCon CNP for patients with achondroplasia (ACH). TransCon CNP is an investigational long-acting prodrug of CNP in development for the treatment of ACH in children.  

Adebola Giwa, MD Associate Medical Director, Clinical Development
Ascendis Pharma

Carl Decker, PhD Clinical Scientist, Clinical Development
Ascendis Pharma

The latest information on the development of Infigratinib for patients with achondroplasia. Infigratinib is an orally bioavailable and selective FGFR1/2/3 selective tyrosine kinase inhibitor in development for FGFR-related conditions. Infigratinib in children with achondroplasia (ACH): design of PROPEL2 – a phase 2, open-label, dose-escalation and dose-expansion study

Anne Lee Director, Global Patient Advocacy
QED Therapeutics

Daniela Rogoff, MD, Phd Vice President, Clinical Development
QED Therapeutics